Deutsche Bank’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $263K | Buy |
189,487
+24,832
| +15% | +$34.1K | ﹤0.01% | 2884 |
|
|
2025
Q4 | $265K | Buy |
164,655
+8,103
| +5% | +$17K | ﹤0.01% | 2879 |
|
|
2025
Q3 | $427K | Buy |
156,552
+24,859
| +19% | +$82.7K | ﹤0.01% | 2633 |
|
|
2025
Q2 | $479K | Sell |
131,693
-29,424
| -18% | -$80.8K | ﹤0.01% | 2476 |
|
|
2025
Q1 | $309K | Sell |
161,117
-19,931
| -11% | -$40.7K | ﹤0.01% | 2737 |
|
|
2024
Q4 | $344K | Buy |
181,048
+70,663
| +64% | +$123K | ﹤0.01% | 2817 |
|
|
2024
Q3 | $146K | Buy |
+110,385
| New | +$147K | ﹤0.01% | 3077 |
|
|
2022
Q2 | – | Sell |
-108,193
| Closed | -$78K | – | 4122 |
|
|
2022
Q1 | $78K | Sell |
108,193
-11,236
| -9% | -$24K | ﹤0.01% | 3670 |
|
|
2021
Q4 | $270K | Buy |
119,429
+4,244
| +4% | +$11.6K | ﹤0.01% | 3214 |
|
|
2021
Q3 | $332K | Buy |
115,185
+5,456
| +5% | +$15.6K | ﹤0.01% | 3286 |
|
|
2021
Q2 | $416K | Sell |
109,729
-1,489
| -1% | -$5.01K | ﹤0.01% | 3335 |
|
|
2021
Q1 | $377K | Sell |
111,218
-8,905
| -7% | -$32.1K | ﹤0.01% | 3277 |
|
|
2020
Q4 | $336K | Sell |
120,123
-321,003
| -73% | -$937K | ﹤0.01% | 3166 |
|
|
2020
Q3 | $1.11M | Buy |
441,126
+165,178
| +60% | +$1.45M | ﹤0.01% | 2124 |
|
|
2020
Q2 | $3.75M | Buy |
275,948
+39,046
| +16% | +$404K | ﹤0.01% | 1455 |
|
|
2020
Q1 | $1.8M | Buy |
236,902
+156,950
| +196% | +$1.22M | ﹤0.01% | 1774 |
|
|
2019
Q4 | $504K | Buy |
79,952
+33,721
| +73% | +$160K | ﹤0.01% | 2707 |
|
|
2019
Q3 | $180K | Sell |
46,231
-103,402
| -69% | -$443K | ﹤0.01% | 3259 |
|
|
2019
Q2 | $723K | Buy |
149,633
+52,041
| +53% | +$296K | ﹤0.01% | 3048 |
|
|
2019
Q1 | $797K | Sell |
97,592
-75,677
| -44% | -$519K | ﹤0.01% | 3144 |
|
|
2018
Q4 | $958K | Sell |
173,269
-185,251
| -52% | -$1.45M | ﹤0.01% | 2923 |
|
|
2018
Q3 | $3.17M | Buy |
358,520
+195,825
| +120% | +$1.75M | ﹤0.01% | 2544 |
|
|
2018
Q2 | $1.62M | Sell |
162,695
-298,750
| -65% | -$2.99M | ﹤0.01% | 3104 |
|
|
2018
Q1 | $4.4M | Buy |
461,445
+299,805
| +185% | +$4.19M | ﹤0.01% | 2328 |
|
|
2017
Q4 | $2.4M | Sell |
161,640
-49,800
| -24% | -$826K | ﹤0.01% | 2597 |
|
|
2017
Q3 | $4.16M | Sell |
211,440
-63,751
| -23% | -$980K | ﹤0.01% | 2032 |
|
|
2017
Q2 | $3.95M | Buy |
275,191
+254,050
| +1,202% | +$3.22M | ﹤0.01% | 2088 |
|
|
2017
Q1 | $193K | Sell |
21,141
-3,431
| -14% | -$33.5K | ﹤0.01% | 3613 |
|
|
2016
Q4 | $254K | Buy |
24,572
+10,662
| +77% | +$91.8K | ﹤0.01% | 3546 |
|
|
2016
Q3 | $125K | Sell |
13,910
-13,285
| -49% | -$113K | ﹤0.01% | 3856 |
|
|
2016
Q2 | $202K | Buy |
27,195
+8,001
| +42% | +$69.8K | ﹤0.01% | 3765 |
|
|
2016
Q1 | $172K | Sell |
19,194
-1,097
| -5% | -$8.89K | ﹤0.01% | 3730 |
|
|
2015
Q4 | $260K | Buy |
20,291
+3,898
| +24% | +$39.8K | ﹤0.01% | 3590 |
|
|
2015
Q3 | $156K | Sell |
16,393
-154,994
| -90% | -$1.42M | ﹤0.01% | 3903 |
|
|
2015
Q2 | $1.76M | Buy |
171,387
+166,970
| +3,780% | +$1.42M | ﹤0.01% | 2553 |
|
|
2015
Q1 | $49K | Sell |
4,417
-5,554
| -56% | -$59.1K | ﹤0.01% | 4393 |
|
|
2014
Q4 | $115K | Buy |
9,971
+9,899
| +13,749% | +$142K | ﹤0.01% | 4634 |
|
|
2014
Q3 | $1K | Buy |
72
+33
| +85% | +$758 | ﹤0.01% | 5722 |
|
|
2014
Q2 | $1K | Buy |
+39
| New | +$939 | ﹤0.01% | 5757 |
|
Other funds holding AKBA
VCM
VPM
Deutsche Bank's AKBA Position: Q1 2026 in Review
Deutsche Bank increased its Akebia Therapeutics (AKBA) stake by 15% in Q1 2026, buying an estimated $34.1K and bringing the position to 189,487 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #2884.
Deutsche Bank first reported a position in AKBA in Q2 2014 and has held it in 39 quarters since. The position peaked at $4.4M in Q1 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Deutsche Bank held 189,487 shares of Akebia Therapeutics worth $263K as of Q1 2026.
- Deutsche Bank bought 24,832 Akebia Therapeutics shares in Q1 2026, an estimated $34.1K.
- Akebia Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2884 holding.
- Deutsche Bank first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 39 quarters since.
- Deutsche Bank's Akebia Therapeutics position peaked at $4.4M in Q1 2018.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.